Erbitux - Merck KGaA/Bristol-Myers Squibb

Cost: $137,953 per U.S. patient per year

Nowadays, Erbitux isn't just a cancer drug, which are often pricey in general. It's a targeted cancer drug. Back in 2009, the FDA allowed Merck ($MRK) to narrow Erbitux's indication for advanced colon cancer, changing the label to recommend the drug for treatment of EGFR-expressing tumors only in patients without a mutation in the KRAS gene.

The move may have narrowed Erbitux's patient pool, but the German pharma has said it thinks better efficacy data in a smaller group can help marketing teams stress the med's benefits. Analysts, though, don't appear sold; they expect the med's peak sales to hit $1.25 billion for Merck this year before slipping to $1.1 billion by 2018.

That's not such great news for Merck, for which Erbitux is a No. 2 seller. Its prescription drug business, Serono, is already struggling after not delivering a major new drug since 2013. Right now, though, the drug is on the rise, with sales expanding 5.9% in 2013.

For more:
Special Report: Top 10 best-selling cancer drugs of 2013 - Erbitux
Merck KGaA eyes KRAS-gene focus to boost Erbitux sales
Merck yanks European app for Erbitux in lung cancer
BMS, Lilly's targeted drug Erbitux gets new FDA nod

-- Carly Helfand (email | Twitter)

Erbitux - Merck KGaA/Bristol-Myers Squibb
Read more on

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.